Eventide Dividend Opportunities Fund | |||||
PORTFOLIO OF INVESTMENTS (Unaudited) | |||||
March 31, 2020 | |||||
Shares | Fair Value | ||||
COMMON STOCK - 57.7 % | |||||
AUTO PARTS & EQUIPMENT - 1.0 % | |||||
7,700 | Aptiv PLC | $ 379,148 | |||
BANKS - 0.9 % | |||||
4,000 | First Republic Bank | 329,120 | |||
BUILDING MATERIALS - 2.6 % | |||||
9,100 | Vulcan Materials Co. | 983,437 | |||
CHEMICALS - 2.3 % | |||||
1,900 | Sherwin-Williams Co. | 873,088 | |||
DISTRIBUTION/WHOLESALE - 0.5 % | |||||
1,000 | Pool Corp. | 196,770 | |||
ELECTRIC - 16.0 % | |||||
85,700 | Algonquin Power & Utilities Corp. | 1,148,380 | |||
38,100 | Atlantica Yield PLC | 849,630 | |||
25,200 | CMS Energy Corp. | 1,480,500 | |||
6,100 | NextEra Energy, Inc. | 1,467,782 | |||
12,600 | WEC Energy Group, Inc. | 1,110,438 | |||
6,056,730 | |||||
ELECTRONICS - 2.9 % | |||||
15,200 | Agilent Technologies, Inc. | 1,088,624 | |||
ENVIORNMENTAL CONTROL - 2.4 % | |||||
9,800 | Waste Management, Inc. | 907,088 | |||
FOOD - 3.0 % | |||||
14,800 | Lamb Weston Holdings, Inc. | 845,080 | |||
2,000 | McCormick & Co., Inc. | 282,420 | |||
1,127,500 | |||||
HEALTHCARE-PRODUCTS - 1.7 % | |||||
6,500 | Zimmer Biomet Holdings, Inc. | 657,020 | |||
HOME BUILDERS - 0.8 % | |||||
9,200 | DR Horton, Inc. | 312,800 | |||
INTERNET - 0.7 % | |||||
3,100 | Cogent Communications Holdings, Inc. | 254,107 | |||
MACHINERY-DIVERSIFIED - 3.9 % | |||||
4,900 | IDEX Corp. | 676,739 | |||
12,600 | Xylem, Inc. | 820,638 | |||
1,497,377 | |||||
MISCELLANEOUS MANUFACTURING - 1.4 % | |||||
6,500 | Trane Technologies PLC | 536,835 | |||
PHARMACEUTICALS - 2.5 % | |||||
8,100 | Zoetis, Inc. | 953,289 | |||
RETAIL - 2.7 % | |||||
12,100 | Lowe's Cos., Inc. | 1,041,205 | |||
SEMICONDUCTORS - 5.1% | |||||
5,700 | KLA Corp. | 819,318 | |||
5,800 | Skyworks Solutions, Inc. | 518,404 | |||
10,900 | Teradyne, Inc. | 590,453 | |||
1,928,175 | |||||
Eventide Dividend Opportunities Fund | |||||
PORTFOLIO OF INVESTMENTS (Unaudited)(Continued) | |||||
March 31, 2020 | |||||
Shares | Fair Value | ||||
COMMON STOCK - 57.7 % (Continued) | |||||
SOFTWARE - 5.5 % | |||||
700 | Constellation Software, Inc. | $ 635,852 | |||
19,700 | Dynatrace, Inc. 1 | 469,648 | |||
6,200 | Jack Henry & Associates, Inc. | 962,488 | |||
2,067,988 | |||||
TRANSPORTATION - 1.8 % | |||||
5,100 | Old Dominion Freight Line, Inc. | 669,426 | |||
TOTAL COMMON STOCK (Cost $24,277,945) | 21,859,727 | ||||
REAL ESTATE INVESTMENT TRUSTS (REITs) - 19.8 % | |||||
7,800 | Alexandria Real Estate Equities, Inc. | 1,069,068 | |||
9,600 | Crown Castle International Corp. | 1,386,240 | |||
2,600 | Equinix, Inc. | 1,623,882 | |||
12,200 | Equity LifeStyle Properties, Inc. | 701,256 | |||
65,800 | Hannon Armstrong Sustainable Infrastructure Capital, Inc. | 1,342,978 | |||
16,900 | Prologis, Inc. | 1,358,253 | |||
TOTAL REAL ESTATE INVESTMENT TRUSTS (REITs) (Cost $7,844,651) | 7,481,677 | ||||
LIMITED PARTNERSHIPS - 7.3 % | |||||
ELECTRIC - 3.2 % | |||||
28,900 | Brookfield Renewable Partners LP | 1,227,961 | |||
ENERGY-ALTERNATIVE SOURCES - 4.1 % | |||||
35,700 | NextEra Energy Partners LP | 1,535,100 | |||
TOTAL LIMITED PARTNERSHIPS (Cost $2,804,271) | 2,763,061 | ||||
PREFERRED STOCK - 1.0 % | |||||
REAL ESTATE INVESTMENT TRUST (REIT) - 1.1 % | |||||
1,250 | Crown Castle International Corp., 6.88%, 8/1/2020 | 400,000 | |||
TOTAL PREFERRED STOCK (Cost $339,240) | 400,000 | ||||
Par Value | |||||
CORPORATE BONDS - 2.1 % | |||||
BIOTECHNOLOGY - 0.3 % | |||||
$ 100,000 | Exact Sciences Corp., 1.00%, 1/15/2025 | 108,929 | |||
INVESTMENT COMPANIES - 0.5 % | |||||
210,000 | Calvert Impact Capital, Inc., 1.50%, 11/13/2020 2 | 210,000 | |||
PHARMACEUTICALS - 1.3 % | |||||
237,000 | Neurocrine Biosciences, Inc., 2.25%, 5/15/2024 | 304,905 | |||
116,000 | Sarepta Therapeutics, Inc., 1.50%, 11/15/2024 | 176,366 | |||
481,271 | |||||
TOTAL CORPORATE BONDS (Cost $886,422) | 800,200 | ||||
Eventide Dividend Opportunities Fund | |||||
PORTFOLIO OF INVESTMENTS (Unaudited)(Continued) | |||||
March 31, 2020 | |||||
Shares | Fair Value | ||||
SHORT-TERM INVESTMENT - 8.2 % | |||||
102,414 | Fidelity Investments Money Market Fund - Institutional Class, 0.30% 3 | $ 102,414 | |||
3,001,187 | First American Government Obligations Fund - Class U, 0.45% 3 | 3,001,187 | |||
TOTAL SHORT-TERM INVESTMENT (Cost $3,103,601) | 3,103,601 | ||||
TOTAL INVESTMENTS - 96.2 % (Cost $39,256,130) | $ 36,408,266 | ||||
OTHER ASSETS IN EXCESS OF LIABILITIES - 3.8 % | 1,450,752 | ||||
TOTAL NET ASSETS - 100.0 % | $ 37,859,018 | ||||
LP - Limited Partnership | |||||
PLC - Public Limited Company | |||||
1. Non-Income producing security. | |||||
2. Illiquid security. Total value of all such securities as of March 31, 2020 amounted to $210,000 and represented 0.55% of Total Net Assets. | |||||
3. Interest rate reflects seven-day effective yield on March 31, 2020. |
Eventide Gilead Fund | ||||||||||
PORTFOLIO OF INVESTMENTS (Unaudited) | ||||||||||
March 31, 2020 | ||||||||||
Shares | Fair Value | |||||||||
COMMON STOCK - 86.8 % | ||||||||||
ADVERTISING - 2.7 % | ||||||||||
300,000 | Trade Desk, Inc. 1 | $ 57,900,000 | ||||||||
AUTO PARTS & EQUIPMENT - 2.3 % | ||||||||||
537,000 | Aptiv PLC | 26,441,880 | ||||||||
718,000 | Magna International, Inc. | 22,918,560 | ||||||||
49,360,440 | ||||||||||
BIOTECHNOLOGY - 5.3 % | ||||||||||
600,000 | Avrobio, Inc. 1 | 9,336,000 | ||||||||
602,000 | Biohaven Pharmaceutical Holding Co. Ltd. 1 | 20,486,060 | ||||||||
618,646 | Essa Pharma, Inc. 1,2 | 2,350,856 | ||||||||
787,000 | Exact Sciences Corp. 1 | 45,646,000 | ||||||||
430,000 | Magenta Therapeutics, Inc. 1 | 2,700,400 | ||||||||
450,000 | Phathom Pharmaceuticals, Inc. 1 | 11,619,000 | ||||||||
430,000 | Sage Therapeutics, Inc. 1 | 12,349,600 | ||||||||
1,720,608 | Stemline Therapeutics, Inc. 1 | 8,327,743 | ||||||||
112,815,659 | ||||||||||
BUILDING MATERIALS - 5.3 % | ||||||||||
255,000 | Lennox International, Inc. | 46,356,450 | ||||||||
299,000 | Trex Co., Inc. 1 | 23,961,860 | ||||||||
377,000 | Vulcan Materials Co. | 40,742,390 | ||||||||
111,060,700 | ||||||||||
COMMERCIAL SERVICES - 3.3 % | ||||||||||
111,000 | Cintas Corp. | 19,227,420 | ||||||||
773,000 | Rollins, Inc. | 27,936,220 | ||||||||
158,000 | Verisk Analytics, Inc. | 22,022,040 | ||||||||
69,185,680 | ||||||||||
COMPUTERS - 3.9 % | ||||||||||
987,000 | Crowdstrike Holdings, Inc. 1 | 54,956,160 | ||||||||
420,000 | Varonis Systems, Inc. 1 | 26,741,400 | ||||||||
81,697,560 | ||||||||||
DISTRIBUTION/WHOLESALE - 1.7 % | ||||||||||
185,000 | Pool Corp. | 36,402,450 | ||||||||
ELECTRIC - 0.8 % | ||||||||||
736,000 | Atlantica Yield PLC | 16,412,800 | ||||||||
ELECTRICAL COMPONENTS & EQUIPMENT - 1.1 % | ||||||||||
280,000 | Novanta, Inc. 1 | 22,366,400 | ||||||||
ELECTRONICS - 5.5 % | ||||||||||
71,000 | Mettler-Toledo International, Inc. 1 | 49,026,210 | ||||||||
214,000 | Roper Technologies, Inc. | 66,727,340 | ||||||||
115,753,550 | ||||||||||
ENVIRONMENTAL CONTROL - 2.9 % | ||||||||||
804,000 | Waste Connections, Inc. | 62,310,000 | ||||||||
FOOD - 0.9 % | ||||||||||
203,000 | Lamb Weston Holdings, Inc. | 11,591,300 | ||||||||
58,000 | McCormick & Co., Inc. | 8,190,180 | ||||||||
19,781,480 | ||||||||||
HEALTHCARE-PRODUCTS - 2.2 % | ||||||||||
143,000 | IDEXX Laboratories, Inc. 1 | 34,640,320 | ||||||||
25,000 | Intuitive Surgical, Inc. 1 | 12,380,250 | ||||||||
47,020,570 | ||||||||||
HOME BUILDERS - 1.0 % | ||||||||||
634,000 | DR Horton, Inc. | 21,556,000 | ||||||||
Eventide Gilead Fund | ||||||||||
PORTFOLIO OF INVESTMENTS (Unaudited)(Continued) | ||||||||||
March 31, 2020 | ||||||||||
Shares | Fair Value | |||||||||
COMMON STOCK - 86.8 % (Continued) | ||||||||||
INTERNET - 3.2 % | ||||||||||
108,000 | Okta, Inc. 1 | $ 13,204,080 | ||||||||
141,837 | Palo Alto Networks, Inc. 1 | 23,255,594 | ||||||||
573,000 | Wayfair, Inc. 1 | 30,621,120 | ||||||||
67,080,794 | ||||||||||
MACHINERY-DIVERSIFIED - 2.3 % | ||||||||||
759,000 | Xylem, Inc. | 49,433,670 | ||||||||
PHARMACEUTICALS - 13.3 % | ||||||||||
1,801,000 | Aimmune Therapeutics, Inc. 1 | 25,970,420 | ||||||||
1,123,000 | Ascendis Pharma A/S - ADR 1 | 126,461,030 | ||||||||
1,344,376 | Collegium Pharmaceutical, Inc. 1 | 21,953,660 | ||||||||
590,602 | Entasis Therapeutics Holdings, Inc. 1,2 | 1,430,733 | ||||||||
206,000 | GW Pharmaceuticals PLC 1 | 18,039,420 | ||||||||
301,600 | Myovant Sciences Ltd. 1 | 2,277,080 | ||||||||
416,512 | Sarepta Therapeutics, Inc. 1 | 40,743,204 | ||||||||
1,824,000 | Zogenix, Inc. 1 | 45,107,520 | ||||||||
281,983,067 | ||||||||||
RETAIL - 2.3 % | ||||||||||
565,000 | Lowe's Cos., Inc. | 48,618,250 | ||||||||
SEMICONDUCTORS - 6.6 % | ||||||||||
172,000 | ASML Holding NV - ADR | 45,002,080 | ||||||||
450,000 | Inphi Corp. 1 | 35,626,500 | ||||||||
201,000 | Lam Research Corp. | 48,240,000 | ||||||||
117,400 | Skyworks Solutions, Inc. | 10,493,212 | ||||||||
139,361,792 | ||||||||||
SOFTWARE - 18.4 % | ||||||||||
329,000 | Datadog, Inc. 1 | 11,837,420 | ||||||||
2,018,000 | Dynatrace, Inc. 1 | 48,109,120 | ||||||||
1,218,000 | Five9, Inc. 1 | 93,128,280 | ||||||||
332,000 | HubSpot, Inc. 1 | 44,219,080 | ||||||||
86,000 | MongoDB, Inc. 1 | 11,742,440 | ||||||||
121,000 | RingCentral, Inc. 1 | 25,641,110 | ||||||||
947,000 | Smartsheet, Inc. 1 | 39,309,970 | ||||||||
428,000 | Splunk, Inc. 1 | 54,026,440 | ||||||||
685,000 | Twilio, Inc. 1 | 61,300,650 | ||||||||
389,314,510 | ||||||||||
TRANSPORTATION - 1.8 % | ||||||||||
202,500 | Old Dominion Freight Line, Inc. | 26,580,150 | ||||||||
220,000 | XPO Logistics, Inc. 1 | 10,725,000 | ||||||||
37,305,150 | ||||||||||
TOTAL COMMON STOCK (Cost $1,627,783,161) | 1,836,720,522 | |||||||||
REAL ESTATE INVESTMENT TRUSTS (REITs) - 2.2 % | ||||||||||
235,000 | Crown Castle International Corp. | 33,934,000 | ||||||||
635,000 | Hannon Armstrong Sustainable Infrastructure Capital, Inc. | 12,960,350 | ||||||||
TOTAL REAL ESTATE INVESTMENT TRUSTS (REITs) (Cost $30,087,774) | 46,894,350 | |||||||||
LIMITED PARTNERSHIPS - 4.0 % | ||||||||||
ELECTRIC - 1.7 % | ||||||||||
824,000 | Brookfield Renewable Partners LP | 35,011,760 | ||||||||
ENERGY-ALTERNATIVE SOURCES - 2.3 % | ||||||||||
1,135,000 | NextEra Energy Partners LP | 48,805,000 | ||||||||
TOTAL LIMITED PARTNERSHIPS (Cost $73,947,361) | 83,816,760 | |||||||||
Eventide Gilead Fund | ||||||||||
PORTFOLIO OF INVESTMENTS (Unaudited)(Continued) | ||||||||||
March 31, 2020 | ||||||||||
Shares | Fair Value | |||||||||
PREFERRED STOCK - 2.4 % | ||||||||||
PHARMACEUTICALS - 2.4 % | ||||||||||
179,406 | Beta Bionic Series B 1,2,3,4,5,6 | $ 27,269,712 | ||||||||
3,982,940 | Peloton Therapeutics, Inc. 1,2,3,5,6 | 3,424,532 | ||||||||
7,263,746 | Pliant Therapeutics Series B 1,2,3,4,5,6 | 12,628,022 | ||||||||
3,825,136 | Pliant Therapeutics Series C 1,2,3,4,5,6 | 6,649,999 | ||||||||
TOTAL PREFERRED STOCK (Cost $44,400,029) | 49,972,265 | |||||||||
Par Value | ||||||||||
CORPORATE BONDS - 1.4 % | ||||||||||
INVESTMENT COMPANIES - 1.4 % | ||||||||||
$ 15,000,000 | Calvert Impact Capital, Inc., 1.50%, 11/13/2020 2 | 15,000,000 | ||||||||
15,000,000 | Calvert Impact Capital, Inc., 1.75%, 11/15/2021 2 | 15,000,000 | ||||||||
TOTAL CORPORATE BONDS (Cost $30,000,000) | 30,000,000 | |||||||||
Contracts 7 | Counterparty | Expiration Date - Exercise Price | Notional Value | |||||||
CALL OPTIONS PURCHASED - 0.0 % | ||||||||||
2,500 | Wayfair, Inc. | Interactive Broker | 1/15/2021 - $120 | $ 30,000,000 | 906,250 | |||||
TOTAL CALL OPTIONS PURCHASED (Cost $1,241,070) | 906,250 | |||||||||
PUT OPTIONS PURCHASED - 0.2 % | ||||||||||
2,060 | iShares Expanded Tech-Software | Interactive Broker | 5/15/2020 - $210 | 43,260,000 | 2,803,660 | |||||
850 | iShares Expanded Tech-Software | Interactive Broker | 5/15/2020 - $220 | 18,700,000 | 1,640,500 | |||||
TOTAL PUT OPTIONS PURCHASED (Cost $1,252,078) | 4,444,160 | |||||||||
Shares | ||||||||||
SHORT-TERM INVESTMENTS - 0.5 % | ||||||||||
10,786,724 | Fidelity Investments Money Market Fund - Institutional Class, 0.30% 8 | 10,786,724 | ||||||||
TOTAL SHORT-TERM INVESTMENTS (Cost $10,786,724) | 10,786,724 | |||||||||
TOTAL INVESTMENTS - 97.5 % (Cost $1,819,498,197) | $ 2,063,541,031 | |||||||||
OTHER ASSETS IN EXCESS OF LIABILITIES - 2.5 % | 53,433,077 | |||||||||
TOTAL NET ASSETS - 100.0 % | $ 2,116,974,108 | |||||||||
ADR- American Depositary Receipt | ||||||||||
LP - Limited Partnership | ||||||||||
PLC - Public Limited Company | ||||||||||
1. Non-Income producing security. | ||||||||||
2. Illiquid security. As of March 31, 2020, represented 3.96% of Total Net Assets. | ||||||||||
3. Security fair valued as of March 31, 2020 in accordance with the procedures approved by the Board of Trustees. Total value of all such securities as March 31, 2020 amounted to $49,972,265, which represents approximately 2.36% of net assets of the Fund. | ||||||||||
4. Affiliated company - the Fund holds in excess of 5% of the outstanding voting securities of this company. | ||||||||||
5. Private investment. | ||||||||||
6. Restricted security. | ||||||||||
7. Each contract is equivalent to 100 shares of the underlying common stock. | ||||||||||
8. Interest rate reflects seven-day effective yield on March 31, 2020. |
Eventide Healthcare & Life Sciences Fund | |||||||||
PORTFOLIO OF INVESTMENTS (Unaudited) | |||||||||
March 31, 2020 | |||||||||
Shares | Fair Value | ||||||||
COMMON STOCK - 86.1 % | |||||||||
BIOTECHNOLOGY - 38.0 % | |||||||||
142,900 | Acceleron Pharma, Inc. 1 | $ 12,842,423 | |||||||
160,000 | Allakos, Inc. 1 | 7,118,400 | |||||||
297,300 | Argenx SE - ADR 1 | 39,163,329 | |||||||
1,305,307 | AvroBio, Inc. 1 | 20,310,577 | |||||||
1,181,761 | BioHaven Pharmaceutical Holding Co. Ltd. 1 | 40,215,327 | |||||||
462,000 | Blueprint Medicines Corp. 1 | 27,017,760 | |||||||
947,000 | Crinetics Pharmaceuticals, Inc. 1 | 13,920,900 | |||||||
243,000 | Deciphera Pharmaceuticals, Inc. 1 | 10,004,310 | |||||||
213,000 | Eidos Therapeutics, Inc. 1 | 10,434,870 | |||||||
1,391,522 | Essa Pharma, Inc. 1,2,3 | 5,287,785 | |||||||
605,000 | Exact Sciences Corp. 1 | 35,090,000 | |||||||
214,843 | Karuna Therapeutics, Inc. 1 | 15,468,696 | |||||||
1,359,646 | Magenta Therapeutics, Inc. 1 | 8,538,577 | |||||||
301,000 | Mirati Therapeutics, Inc. 1 | 23,137,870 | |||||||
270,000 | Orchard Therapeutics plc - ADR 1 | 2,033,100 | |||||||
30,900 | Regeneron Pharmaceuticals, Inc. 1 | 15,088,161 | |||||||
1,415,000 | Rocket Pharmaceuticals, Inc. 1 | 19,739,250 | |||||||
360,000 | Sage Therapeutics, Inc. 1 | 10,339,200 | |||||||
425,000 | Satsuma Pharmaceuticals, Inc. 1 | 9,146,000 | |||||||
102,500 | Seattle Genetics, Inc. 1 | 11,826,450 | |||||||
2,440,000 | Stemline Therapeutics, Inc. 1 | 11,809,600 | |||||||
226,680 | Syndax Pharmaceuticals, Inc. 1 | 2,486,679 | |||||||
930,000 | Veracyte, Inc. 1 | 22,608,300 | |||||||
45,500 | Vertex Pharmaceuticals, Inc. 1 | 10,826,725 | |||||||
300,000 | Xencor, Inc. 1 | 8,964,000 | |||||||
1,274,100 | Xenon Pharmaceuticals, Inc. 1 | 14,448,294 | |||||||
407,866,583 | |||||||||
HEALTHCARE-PRODUCTS - 1.1 % | |||||||||
119,000 | Repligen Corp. 1 | 11,488,260 | |||||||
HOLDING COMPANIES-DIVERSIFIED - 0.8 % | |||||||||
800,000 | ARYA Sciences Acquisition Corp. 1,3 | 9,032,000 | |||||||
PHARMACEUTICALS - 46.2 % | |||||||||
350,000 | 89bio, Inc. 1 | 8,837,500 | |||||||
2,050,000 | Aimmune Therapeutics, Inc. 1 | 29,561,000 | |||||||
230,000 | Arvinas, Inc. 1 | 9,269,000 | |||||||
575,648 | Ascendis Pharma A/S - ADR 1 | 64,823,721 | |||||||
1,083,600 | Collegium Pharmaceutical, Inc. 1 | 17,695,188 | |||||||
288,939 | Entasis Therapeutics Holdings, Inc. 1,2 | 699,955 | |||||||
720,000 | Fennec Pharmaceuticals, Inc. 1 | 4,276,800 | |||||||
51,000 | Galapagos NV 1 | 9,991,920 | |||||||
535,000 | Global Blood Therapeutics, Inc. 1 | 27,333,150 | |||||||
230,000 | GW Pharmaceuticals PLC - ADR 1 | 20,141,100 | |||||||
2,952,899 | Kala Pharmaceuticals, Inc. 1,3 | 25,955,982 | |||||||
1,680,000 | KalVista Pharmaceuticals, Inc. 1,3 | 12,852,000 | |||||||
686,234 | Karuna Pharmaceuticals, Inc. 1 | 49,408,848 | |||||||
1,212,000 | Momenta Pharmaceuticals, Inc. 1 | 32,966,400 | |||||||
621,000 | MyoKardia, Inc. 1 | 29,112,480 | |||||||
498,400 | Myovant Sciences Ltd. 1 | 3,762,920 | |||||||
353,000 | Neurocrine Biosciences, Inc. 1 | 30,552,150 | |||||||
Eventide Healthcare & Life Sciences Fund | |||||||||
PORTFOLIO OF INVESTMENTS (Unaudited)(Continued) | |||||||||
March 31, 2020 | |||||||||
Shares | Fair Value | ||||||||
COMMON STOCK - 86.1 % (Continued) | |||||||||
PHARMACEUTICALS - 46.2 % (Continued) | |||||||||
579,488 | Sarepta Therapeutics, Inc. 1 | $ 56,685,516 | |||||||
1,285,975 | Sutro Biopharma, Inc. 1,3 | 13,116,945 | |||||||
500,000 | uniQure NV 1 | 23,725,000 | |||||||
1,017,300 | Zogenix, Inc. 1 | 25,157,829 | |||||||
495,925,404 | |||||||||
TOTAL COMMON STOCK (Cost $853,708,197) | 924,312,247 | ||||||||
PREFERRED STOCK - 5.8 % | |||||||||
PHARMACEUTICALS - 5.8 % | |||||||||
122,828 | Beta Bionic Series B 1,2,4,5,6 | 18,669,856 | |||||||
5,000,000 | Goldfinch Biopharma, Inc. 1,2,4,5,6 | 4,750,000 | |||||||
1,528,871 | Peloton Therapeutics, Inc. 1,2,4,5,6 | 1,314,523 | |||||||
3,631,873 | Pliant Therapeutics Series B 1,2,4,5,6 | 6,314,011 | |||||||
1,639,344 | Pliant Therapeutics Series C 1,2,4,5,6 | 2,850,000 | |||||||
1,941,748 | Praxis Precision Medicines, Inc. 1,2,4,5,6 | 9,500,002 | |||||||
558,382 | Satsuma Pharmaceuticals, Inc. 1,2,3,5,6 | 11,415,562 | |||||||
428,572 | Zentalis Pharmaceuticals LLC 1,2,4,5,6 | 7,125,009 | |||||||
TOTAL PREFERRED STOCK (Cost $54,500,026) | 61,938,963 | ||||||||
WARRANTS - 0.1 % | |||||||||
651,900 | Immunovant, Inc. | 1,564,560 | |||||||
TOTAL WARRANTS (Cost $825,188) | 1,564,560 | ||||||||
SHORT-TERM INVESTMENTS - 4.6 % | |||||||||
3,113,457 | Fidelity Investments Money Market Fund - Institutional Class, 0.30% 7 | 3,113,457 | |||||||
46,060,937 | First American Government Obligations Fund - Class U, 0.45% 7 | 46,060,937 | |||||||
TOTAL SHORT-TERM INVESTMENTS (Cost $49,174,394) | 49,174,394 | ||||||||
TOTAL INVESTMENTS - 96.6 % (Cost $958,207,805) | $ 1,036,990,164 | ||||||||
OTHER ASSETS IN EXCESS OF LIABILITIES - 3.4 % | 36,058,349 | ||||||||
TOTAL NET ASSETS - 100.0 % | $ 1,073,048,513 | ||||||||
ADR - American Depositary Receipt | |||||||||
LLC - Limited Liability Company | |||||||||
PLC - Public Limited Company | |||||||||
1. Non-Income producing security. | |||||||||
2. Illiquid security. As of March 31, 2020 represented 6.33% of Total Net Assets. | |||||||||
3. Affiliated company - the Fund holds in excess of 5% of the outstanding voting securities of this company. | |||||||||
4. Security fair valued as of March 31, 2020 in accordance with the procedures approved by the Board of Trustees. Total value of all such securities as March 31, 2020 amounted to $50,523,401, which represents approximately 4.71% of net assets of the Fund. | |||||||||
5. Private investment. | |||||||||
6. Restricted security. | |||||||||
7. Interest rate reflects seven-day effective yield on March 31, 2020. |
Eventide Limited-Term Bond Fund | |||||||||
PORTFOLIO OF INVESTMENTS (Unaudited) | |||||||||
March 31, 2020 | |||||||||
Shares | Fair Value | ||||||||
PREFERRED STOCK - 1.1 % | |||||||||
BANKS - 0.5 % | |||||||||
7,800 | BOK Financial Corp., 5.38%, 6/30/2056 | $ 183,300 | |||||||
6,746 | Hancock Whitney Corp., 5.95%, 6/15/2045 | 145,107 | |||||||
328,407 | |||||||||
REAL ESTATE INVESTMENT TRUSTS (REITs) - 0.3 % | |||||||||
8,236 | Public Storage, 5.38%, Perpetual | 198,652 | |||||||
TRUCKING & LEASING - 0.3 % | |||||||||
7,782 | GATX Corp., 5.63%, 5/30/2066 | 185,227 | |||||||
TOTAL PREFERRED STOCK (Cost $779,420) | 712,286 | ||||||||
Par Value | |||||||||
CORPORATE BONDS - 36.5 % | |||||||||
BANKS - 2.1 % | |||||||||
$ 700,000 | PNC Financial Services Group, Inc., 2.20%, 11/1/2024 | 718,907 | |||||||
650,000 | SVB Financial Group, 3.50%, 1/29/2025 | 655,844 | |||||||
1,374,751 | |||||||||
BIOTECHNOLOGY - 0.9 % | |||||||||
565,000 | Celgene Corp., 3.25%, 2/20/2023 | 578,137 | |||||||
COMPUTERS - 2.1 % | |||||||||
700,000 | Apple, Inc., 2.85%, 2/23/2023 | 731,304 | |||||||
650,000 | NetApp, Inc., 3.30%, 9/29/2024 | 640,522 | |||||||
1,371,826 | |||||||||
DIVERSIFIED FINANCIAL SERVICES - 4.8 % | |||||||||
700,000 | E*TRADE Financial Corp., 2.95%, 8/24/2022 | 691,967 | |||||||
250,000 | Eaton Vance Corp., 3.50%, 4/6/2027 | 248,202 | |||||||
650,000 | Intercontinental Exchange, Inc., 4.00%, 10/15/2023 | 681,717 | |||||||
400,000 | Legg Mason, Inc., 3.95%, 7/15/2024 | 397,675 | |||||||
200,000 | Legg Mason, Inc., 4.75%, 3/15/2026 | 200,754 | |||||||
650,000 | Nasdaq, Inc., 4.25%, 6/1/2024 | 680,955 | |||||||
300,000 | Stifel Financial Corp., 4.25%, 7/18/2024 | 305,724 | |||||||
3,206,994 | |||||||||
ELECTRIC - 2.5 % | |||||||||
279,000 | Avangrid, Inc., 3.15%, 12/1/2024 | 278,022 | |||||||
250,000 | CMS Energy Corp., 3.60%, 11/15/2024 | 277,619 | |||||||
360,000 | CMS Energy Corp., 3.88%, 3/1/2024 | 367,474 | |||||||
500,000 | Florida Power & Light Co., 3.13%, 12/1/2025 | 511,768 | |||||||
250,000 | NextEra Energy Capital Holdings, Inc., 1.95%, 9/1/2022 | 247,051 | |||||||
1,681,934 | |||||||||
ELECTRICAL COMPONENTS & EQUIPMENT - 0.6 % | |||||||||
400,000 | Emerson Electric Co., 2.63%, 12/1/2021 | 409,024 | |||||||
ELECTRONICS - 1.0 % | |||||||||
650,000 | Roper Technolgies, Inc., 3.65%, 9/15/2023 | 667,016 | |||||||
ENVIRONMENTAL CONTROL - 1.0 % | |||||||||
650,000 | Waste Management, Inc., 3.13%, 3/1/2025 | 674,138 | |||||||
INSURANCE - 3.6 % | |||||||||
650,000 | Aflac, Inc., 2.88%, 10/15/2026 | 643,250 | |||||||
650,000 | CNA Financial Corp., 3.95%, 5/15/2024 | 673,401 | |||||||
250,000 | Old Republic International Corp., 4.88%, 10/1/2024 | 264,486 | |||||||
750,000 | Primerica, Inc., 4.75%, 7/15/2022 | 775,900 | |||||||
2,357,037 | |||||||||
PHARMACEUTICALS - 1.1 % | |||||||||
700,000 | Zoetis, Inc., 3.25%, 2/1/2023 | 714,634 | |||||||
PIPELINES - 0.6 % | |||||||||
400,000 | ONEOK, Inc., 4.25%, 2/1/2022 | 386,169 | |||||||
Eventide Limited-Term Bond Fund | |||||||||
PORTFOLIO OF INVESTMENTS (Unaudited)(Continued) | |||||||||
March 31, 2020 | |||||||||
Par Value | Fair Value | ||||||||
CORPORATE BONDS - 36.5 % (Continued) | |||||||||
REAL ESTATE INVESTMENT TRUSTS (REITs) - 6.1 % | |||||||||
$ 650,000 | American Tower Corp., 3.38%, 5/15/2024 | $ 652,584 | |||||||
700,000 | Boston Properties LP, 3.13%, 9/1/2023 | 700,695 | |||||||
450,000 | CubeSmart LP, 4.80%, 7/15/2022 | 454,716 | |||||||
300,000 | Healthpeak Properties, Inc., 4.25%, 11/15/2023 | 284,032 | |||||||
400,000 | Kimco Realty Corp., 3.20%, 5/1/2021 | 393,741 | |||||||
200,000 | Prologis LP, 3.75%, 11/1/2025 | 212,584 | |||||||
700,000 | Ventas Realty LP, 3.10%, 1/15/2023 | 686,004 | |||||||
650,000 | Welltower, Inc., 3.63%, 3/15/2024 | 639,129 | |||||||
4,023,485 | |||||||||
RETAIL - 3.0 % | |||||||||
450,000 | AutoZone, Inc., 2.88%, 1/15/2023 | 451,124 | |||||||
250,000 | AutoZone, Inc., 3.25%, 4/15/2025 | 249,635 | |||||||
500,000 | AutoZone, Inc., 3.50%, 11/15/2024 | 487,051 | |||||||
450,000 | Lowe's Cos., Inc., 3.12%, 4/15/2022 | 446,917 | |||||||
350,000 | O'Reilly Automotive, Inc., 3.85%, 6/15/2023 | 349,317 | |||||||
1,984,044 | |||||||||
SEMICONDUCTORS - 3.5 % | |||||||||
225,000 | KLA-Tencor Corp., 4.65%, 11/1/2024 | 237,810 | |||||||
574,000 | Lam Research Corp., 3.80%, 3/15/2025 | 592,215 | |||||||
700,000 | Micron Technology, Inc., 4.64%, 2/6/2024 | 712,266 | |||||||
500,000 | NVIDIA Corp., 2.20%, 9/16/2021 | 504,102 | |||||||
250,000 | NVIDIA Corp., 3.20%, 9/16/2026 | 278,980 | |||||||
2,325,373 | |||||||||
TELECOMMUNICATIONS - 1.0 % | |||||||||
650,000 | Juniper Networks, Inc., 4.50%, 3/15/2024 | 686,868 | |||||||
TRANSPORTATION - 2.6 % | |||||||||
400,000 | JB Hunt Transport Services, Inc., 3.30%, 8/15/2022 | 384,576 | |||||||
329,000 | JB Hunt Transport Services, Inc., 3.85%, 3/15/2024 | 340,635 | |||||||
250,000 | Kansas City Southern, 3.85%, 11/15/2023 | 247,785 | |||||||
350,000 | Norfolk Southern Corp., 2.90%, 2/15/2023 | 355,491 | |||||||
400,000 | Norfolk Southern Corp., 3.00%, 4/1/2022 | 401,552 | |||||||
1,730,039 | |||||||||
TOTAL CORPORATE BONDS (Cost $24,724,206) | 24,171,469 | ||||||||
MUNICIPAL BONDS - 1.7 % | |||||||||
DELAWARE - 0.1 % | |||||||||
35,000 | Delaware State Housing Authority, 2.75%, 12/1/2041 | 35,364 | |||||||
MARYLAND - 0.2 % | |||||||||
145,000 | Maryland Community Development Administration, 3.24%, 9/1/2048 | 151,344 | |||||||
MASSACHUSETTS - 0.3 % | |||||||||
20,000 | Massachusetts Housing Finance Agency, 3.28%, 12/1/2020 | 20,178 | |||||||
140,000 | Massachusetts Housing Finance Agency, 4.00%, 6/1/2039 | 146,900 | |||||||
167,078 | |||||||||
NEW YORK - 1.1 % | |||||||||
500,000 | New York City Housing Development Corp., 1.93%, 2/1/2025 | 499,935 | |||||||
250,000 | New York State Housing Finance Agency, 2.20%, 11/1/2024 | 250,674 | |||||||
750,609 | |||||||||
TOTAL MUNICIPAL BONDS (Cost $1,095,946) | 1,104,395 | ||||||||
Eventide Limited-Term Bond Fund | |||||||||
PORTFOLIO OF INVESTMENTS (Unaudited)(Continued) | |||||||||
March 31, 2020 | |||||||||
Par Value | Fair Value | ||||||||
AGENCY COLLATERAL CMO - 2.8 % | |||||||||
$ 149,895 | Fannie Mae Interest Strip, 3.00%, 11/25/2042 | $ 161,875 | |||||||
10,420 | Fannie Mae REMICS, 2.00%, 7/25/2037 | 10,434 | |||||||
34,656 | Fannie Mae REMICS, 2.50%, 12/25/2028 | 35,591 | |||||||
226,719 | Fannie Mae REMICS, 3.00%, 8/25/2036 | 241,820 | |||||||
250,000 | Fannie Mae REMICS, 3.00%, 12/25/2040 | 267,890 | |||||||
336,033 | Fannie Mae REMICS, 3.00%, 10/25/2042 | 354,209 | |||||||
169,820 | Fannie Mae REMICS, 3.50%, 10/25/2042 | 185,034 | |||||||
58,997 | Freddie Mac REMICS, 2.25%, 2/15/2028 | 60,394 | |||||||
170,967 | Freddie Mac REMICS, 3.00%, 12/15/2044 | 182,366 | |||||||
240,311 | Freddie Mac REMICS, 3.00%, 6/15/2046 | 254,734 | |||||||
99,730 | Government National Mortgage Association, 3.50%, 7/20/2023 | 104,174 | |||||||
TOTAL AGENCY COLLATERAL CMO (Cost $1,769,000) | 1,858,521 | ||||||||
ASSET BACKED SECURITIES - 13.6 % | |||||||||
165,022 | FGLMC Collateral, 3.00%, 5/1/2046 | 174,639 | |||||||
135,917 | FGLMC Collateral, 3.50%, 5/1/2046 | 144,834 | |||||||
1,400,000 | FHLMC Collateral, 2.83%, 11/1/2046, Monthly US LIBOR +1.6170% 1 | 1,414,636 | |||||||
2,522 | FHLMC Collateral, 3.89%, 1/1/2024, H15T1Y +2.1390% 1 | 2,555 | |||||||
3,010 | FHLMC Collateral, 4.31%, 1/1/2024, H15T1Y +2.4210% 1 | 3,049 | |||||||
11,279 | FHLMC Collateral, 4.47%, 9/1/2022, H15T1Y +2.0950% 1 | 11,380 | |||||||
830 | FHLMC Collateral, 4.62%, 5/1/2038, Monthly US LIBOR +1.7500% 1 | 838 | |||||||
250,000 | FNMA Collateral, 2.27%, 9/1/2026 | 261,479 | |||||||
728,909 | FNMA Collateral, 2.48%, 8/1/2026 | 770,059 | |||||||
722,404 | FNMA Collateral, 2.52%, 4/1/2023 | 753,042 | |||||||
479,805 | FNMA Collateral, 2.52%, 12/1/2026 | 508,666 | |||||||
250,000 | FNMA Collateral, 2.60%, 9/1/2024 | 265,261 | |||||||
1,712,410 | FNMA Collateral, 2.67%, 1/1/2025 | 1,823,547 | |||||||
680,000 | FNMA Collateral, 2.70%, 12/1/2024 | 723,733 | |||||||
500,000 | FNMA Collateral, 2.73%, 2/1/2025 | 536,333 | |||||||
396,388 | FNMA Collateral, 2.90%, 5/1/2027 | 435,602 | |||||||
190,000 | FNMA Collateral, 2.90%, 12/1/2027 | 210,104 | |||||||
149,490 | FNMA Collateral, 3.00%, 6/1/2036 | 158,407 | |||||||
163,419 | FNMA Collateral, 3.00%, 5/1/2046 | 172,994 | |||||||
1,292 | FNMA Collateral, 3.91%, 9/1/2038, Monthly US LIBOR +1.5340% 1 | 1,304 | |||||||
150,000 | FNMA Collateral, 3.94%, 7/1/2021 | 154,430 | |||||||
13,066 | FNMA Collateral, 4.07%, 3/1/2038, H15T1Y +2.2040% 1 | 13,358 | |||||||
21,910 | FNMA Collateral, 4.40%, 6/1/2036, Monthly US LIBOR +1.6510% 1 | 22,100 | |||||||
16,284 | FNMA Collateral, 4.41%, 7/1/2036, Monthly US LIBOR +1.8940% 1 | 16,634 | |||||||
54,537 | FNMA Collateral, 4.52%, 6/1/2036, H15T1Y +2.1800% 1 | 54,651 | |||||||
2,913 | FNMA Collateral, 4.55%, 8/1/2034, H15T1Y +2.1700% 1 | 2,944 | |||||||
184,544 | FNMA Collateral, 4.56%, 5/1/2020 | 184,285 | |||||||
722 | GNMA Collateral, 6.50%, 1/15/2024 | 793 | |||||||
73 | GNMA Collateral, 6.50%, 4/15/2026 | 80 | |||||||
99 | GNMA Collateral, 7.00%, 9/15/2023 | 105 | |||||||
5,969 | GNMA Collateral, 7.00%, 4/15/2028 | 6,139 | |||||||
483 | GNMA Collateral, 7.50%, 12/15/2023 | 490 | |||||||
2,935 | GNMA2 Collateral, 3.13%, 10/20/2022, H15T1Y +1.5000% 1 | 2,958 | |||||||
6,897 | GNMA2 Collateral, 3.13%, 12/20/2024, H15T1Y +1.5000% 1 | 7,006 | |||||||
3,149 | GNMA2 Collateral, 3.13%, 12/20/2032, H15T1Y +1.5000% 1 | 3,267 | |||||||
27,692 | GNMA2 Collateral, 3.13%, 10/20/2034, H15T1Y +1.5000% 1 | 28,774 | |||||||
2,418 | GNMA2 Collateral, 3.25%, 7/20/2023, H15T1Y +1.5000% 1 | 2,471 | |||||||
2,321 | GNMA2 Collateral, 3.25%, 8/20/2023, H15T1Y +1.5000% 1 | 2,373 | |||||||
4,777 | GNMA2 Collateral, 3.25%, 9/20/2024, H15T1Y +1.5000% 1 | 4,882 | |||||||
2,096 | GNMA2 Collateral, 3.25%, 7/20/2025, H15T1Y +1.5000% 1 | 2,155 | |||||||
9,750 | GNMA2 Collateral, 3.25%, 9/20/2030, H15T1Y +1.5000% 1 | 9,849 | |||||||
Eventide Limited-Term Bond Fund | |||||||||
PORTFOLIO OF INVESTMENTS (Unaudited)(Continued) | |||||||||
March 31, 2020 | |||||||||
Par Value | Fair Value | ||||||||
ASSET BACKED SECURITIES - 13.6 % (Continued) | |||||||||
$ 21,630 | GNMA2 Collateral, 3.25%, 7/20/2031, H15T1Y +1.5000% 1 | $ 22,433 | |||||||
23,477 | GNMA2 Collateral, 3.25%, 7/20/2036, H15T1Y +1.5000% 1 | 23,640 | |||||||
16,564 | GNMA2 Collateral, 3.25%, 8/20/2041, H15T1Y +1.5000% 1 | 17,067 | |||||||
998 | GNMA2 Collateral, 3.88%, 4/20/2024, H15T1Y +1.5000% 1 | 1,008 | |||||||
2,191 | GNMA2 Collateral, 3.88%, 5/20/2024, H15T1Y +1.5000% 1 | 2,251 | |||||||
12,154 | GNMA2 Collateral, 4.00%, 1/20/2023, H15T1Y +1.5000% 1 | 12,399 | |||||||
9,017 | GNMA2 Collateral, 4.00%, 1/20/2024, H15T1Y +1.5000% 1 | 9,228 | |||||||
1,837 | GNMA2 Collateral, 4.00%, 2/20/2024, H15T1Y +1.5000% 1 | 1,880 | |||||||
1,820 | GNMA2 Collateral, 4.00%, 3/20/2024, H15T1Y +1.5000% 1 | 1,863 | |||||||
10,281 | GNMA2 Collateral, 4.00%, 2/20/2025, H15T1Y +1.5000% 1 | 10,568 | |||||||
24,801 | GNMA2 Collateral, 4.00%, 1/20/2032, H15T1Y +1.5000% 1 | 25,636 | |||||||
TOTAL ASSET BACKED SECURITIES (Cost $8,815,900) | 9,020,179 | ||||||||
COMMERCIAL MORTGAGE BACKED SECURITIES - 0.2 % | |||||||||
130,634 | Freddie Mac Multifamily Structured Pass Through Certificates, 1.58%, 4/25/2022 | 131,819 | |||||||
TOTAL COMMERCIAL MORTGAGE BACKED SECURITIES (Cost $130,174) | 131,819 | ||||||||
U.S. GOVERNMENT AGENCIES AND OBLIGATIONS - 38.5 % | |||||||||
1,000,000 | Federal Agricultural Mortgage Corp., 1.62%, 9/4/2025 | 1,025,544 | |||||||
300,000 | Federal Agricultural Mortgage Corp., 1.85%, 9/16/2022 | 301,661 | |||||||
400,000 | Federal Agricultural Mortgage Corp., 2.04%, 6/21/2024 | 417,602 | |||||||
250,000 | Federal Agricultural Mortgage Corp., 2.10%, 6/6/2022 | 257,742 | |||||||
400,000 | Federal Agricultural Mortgage Corp., 2.50%, 1/30/2023 | 419,628 | |||||||
250,000 | Federal Agricultural Mortgage Corp., 2.68%, 2/1/2022 | 259,348 | |||||||
250,000 | Federal Agricultural Mortgage Corp., 2.89%, 4/29/2022 | 261,519 | |||||||
250,000 | Federal Agricultural Mortgage Corp., 3.00%, 2/23/2027 | 273,207 | |||||||
1,000,000 | Federal Farm Credit Banks, 1.21%, 3/3/2025 | 1,025,066 | |||||||
200,000 | Federal Farm Credit Banks, 1.40%, 10/15/2021 | 203,077 | |||||||
1,000,000 | Federal Farm Credit Banks, 1.55%, 1/10/2023 | 1,020,634 | |||||||
400,000 | Federal Farm Credit Banks, 1.59%, 12/10/2021 | 403,383 | |||||||
1,000,000 | Federal Farm Credit Banks, 1.60%, 2/10/2023 | 1,006,952 | |||||||
1,000,000 | Federal Farm Credit Banks, 1.64%, 4/9/2021 | 1,003,514 | |||||||
300,000 | Federal Farm Credit Banks, 1.71%, 12/16/2022 | 301,625 | |||||||
1,000,000 | Federal Farm Credit Banks, 1.84%, 10/13/2023 | 1,000,409 | |||||||
1,500,000 | Federal Farm Credit Banks, 1.92%, 8/4/2025 | 1,512,967 | |||||||
1,500,000 | Federal Farm Credit Banks, 2.02%, 11/4/2025 | 1,500,104 | |||||||
300,000 | Federal Farm Credit Banks, 2.35%, 2/12/2021 | 305,128 | |||||||
300,000 | Federal Farm Credit Banks, 2.40%, 9/21/2026 | 331,718 | |||||||
210,000 | Federal Farm Credit Banks, 2.83%, 9/7/2021 | 217,360 | |||||||
1,500,000 | Federal Home Loan Mortgage Corp., 1.13%, 3/10/2025 2 | 1,499,130 | |||||||
1,500,000 | Federal Home Loan Mortgage Corp., 1.63%, 9/29/2020 | 1,508,285 | |||||||
1,000,000 | Federal Home Loan Mortgage Corp., 1.75%, 10/17/2022 | 1,003,805 | |||||||
1,000,000 | Federal Home Loan Mortgage Corp., 1.75%, 1/22/2024 | 1,008,791 | |||||||
325,000 | Federal Home Loan Mortgage Corp., 1.75%, 9/4/2024 | 328,456 | |||||||
1,000,000 | Federal Home Loan Mortgage Corp., 1.75%, 2/18/2025 | 1,007,921 | |||||||
250,000 | Federal Home Loan Mortgage Corp., 1.80%, 6/16/2023 | 250,672 | |||||||
1,000,000 | Federal Home Loan Mortgage Corp., 1.85%, 7/6/2023 | 1,003,437 | |||||||
1,000,000 | Federal Home Loan Mortgage Corp., 1.90%, 1/17/2024 | 1,003,565 | |||||||
1,000,000 | Federal Home Loan Mortgage Corp., 1.90%, 1/15/2025 | 1,009,026 | |||||||
Eventide Limited-Term Bond Fund | |||||||||
PORTFOLIO OF INVESTMENTS (Unaudited)(Continued) | |||||||||
March 31, 2020 | |||||||||
Par Value | Fair Value | ||||||||
U.S. GOVERNMENT AGENCIES AND OBLIGATIONS - 38.5 % (Continued) | |||||||||
$ 1,000,000 | Federal Home Loan Mortgage Corp., 2.38%, 2/16/2021 | $ 1,016,830 | |||||||
750,000 | Federal Home Loan Mortgage Corp., 2.38%, 1/13/2022 | 776,435 | |||||||
1,000,000 | Federal National Mortgage Association, 2.13%, 4/24/2026 | 1,077,072 | |||||||
TOTAL U.S. GOVERNMENT AGENCIES AND OBLIGATIONS (Cost $25,218,567) | 25,541,613 | ||||||||
TOTAL INVESTMENTS - 94.4 % (Cost $62,533,213) | $ 62,540,282 | ||||||||
OTHER ASSETS IN EXCESS OF LIABILITIES - 5.6 % | 3,708,640 | ||||||||
TOTAL NET ASSETS - 100.0 % | $ 66,248,922 | ||||||||
H15T1Y - US Treasury Yield Curve Rate T-Note Constant Maturity 1 Year | |||||||||
LP - Limited Partnership | |||||||||
1. Floating rate, rate shown represents the rate at March 31, 2020. | |||||||||
2. STEP security |
Eventide Multi-Asset Income Fund | |||||||||
PORTFOLIO OF INVESTMENTS (Unaudited) | |||||||||
March 31, 2020 | |||||||||
Shares | Fair Value | ||||||||
COMMON STOCK - 31.7 % | |||||||||
AUTO PARTS & EQUIPMENT - 0.5 % | |||||||||
11,800 | Aptiv PLC | $ 581,032 | |||||||
BANKS - 0.6 % | |||||||||
8,300 | First Republic Bank | 682,924 | |||||||
BUILDING MATERIALS - 1.4 % | |||||||||
15,600 | Vulcan Materials Co. | 1,685,892 | |||||||
CHEMICALS - 0.9 % | |||||||||
2,400 | Sherwin-Williams Co. | 1,102,848 | |||||||
ELECTRIC - 10.5 % | |||||||||
199,600 | Algonquin Power & Utilities Corp. | 2,674,640 | |||||||
87,600 | Atlantica Yield plc | 1,953,480 | |||||||
44,500 | CMS Energy Corp. | 2,614,375 | |||||||
11,300 | NextEra Energy, Inc. | 2,719,006 | |||||||
27,300 | WEC Energy Group, Inc. | 2,405,949 | |||||||
12,367,450 | |||||||||
ELECTRONICS - 2.0 % | |||||||||
31,900 | Agilent Technologies, Inc. | 2,284,678 | |||||||
ENVIRONMENTAL CONTROL - 1.6 % | |||||||||
20,500 | Waste Management, Inc. | 1,897,480 | |||||||
FOOD - 1.2 % | |||||||||
24,600 | Lamb Weston Holdings, Inc. | 1,404,660 | |||||||
HEALTHCARE-PRODUCTS - 0.8 % | |||||||||
8,700 | Zimmer Biomet Holdings, Inc. | 879,396 | |||||||
HOME BUILDERS - 0.5 % | |||||||||
16,000 | DR Horton, Inc. | 544,000 | |||||||
MACHINERY-DIVERSIFIED - 1.7 % | |||||||||
4,400 | IDEX Corp. | 607,684 | |||||||
21,400 | Xylem, Inc. | 1,393,782 | |||||||
2,001,466 | |||||||||
MISCELLANEOUS MANUFACTURING - 0.9 % | |||||||||
13,300 | Trane Technologies PLC | 1,098,447 | |||||||
PHARMACEUTICALS - 0.6 % | |||||||||
6,100 | Zoetis, Inc. | 717,909 | |||||||
RETAIL - 1.4 % | |||||||||
19,500 | Lowe's Companies, Inc. | 1,677,975 | |||||||
SEMICONDUCTORS - 3.0 % | |||||||||
10,000 | KLA Corp. | 1,437,400 | |||||||
12,000 | Skyworks Solutions, Inc. | 1,072,560 | |||||||
19,500 | Teradyne, Inc. | 1,056,315 | |||||||
3,566,275 | |||||||||
SOFTWARE - 3.4 % | |||||||||
700 | Constellation Software, Inc. | 635,852 | |||||||
38,700 | Dynatrace, Inc. 1 | 922,608 | |||||||
16,000 | Jack Henry & Associates, Inc. | 2,483,840 | |||||||
4,042,300 | |||||||||
Eventide Multi-Asset Income Fund | |||||||||
PORTFOLIO OF INVESTMENTS (Unaudited)(Continued) | |||||||||
March 31, 2020 | |||||||||
Shares | Fair Value | ||||||||
COMMON STOCK - 31.7 % (Continued) | |||||||||
TRANSPORTATION - 0.7 % | |||||||||
5,900 | Old Dominion Freight Line, Inc. | $ 774,434 | |||||||
TOTAL COMMON STOCK (Cost $41,212,054) | 37,309,166 | ||||||||
REAL ESTATE INVESTMENT TRUSTS (REITs) - 12.1 % | |||||||||
16,300 | Alexandria Real Estate Equities, Inc. | 2,234,078 | |||||||
21,300 | Crowne Castle International Corp. | 3,075,720 | |||||||
4,400 | Equinix, Inc. | 2,748,108 | |||||||
25,600 | Equity LifeStyle Properties, Inc. | 1,471,488 | |||||||
143,800 | Hannon Armstrong Sustainable Infrastructure Capital, Inc. | 2,934,958 | |||||||
22,400 | Prologis, Inc. | 1,800,288 | |||||||
TOTAL REAL ESTATE INVESTMENT TRUSTS (REITs) (Cost $14,246,113) | 14,264,640 | ||||||||
LIMITED PARTNERSHIPS - 4.9 % | |||||||||
ELECTRIC - 2.3% | |||||||||
63,300 | Brookfield Renewable Partners LP | 2,689,617 | |||||||
ENERGY-ALTERNATIVE SOURCES - 2.6 % | |||||||||
72,100 | NextEra Energy Partners LP | 3,100,300 | |||||||
TOTAL LIMITED PARTNERSHIPS (Cost $5,032,436) | 5,789,917 | ||||||||
Par Value | |||||||||
CORPORATE BONDS - 23.4 % | |||||||||
BANKS - 2.5 % | |||||||||
$ 850,000 | Bank of America Corp., 3.50%, 5/17/2022, Quarterly US LIBOR +0.6300% 2 | 860,478 | |||||||
290,000 | First Horizon National Corp., 3.50%, 12/15/2020 | 287,238 | |||||||
1,000,000 | PNC Financial Services Group, Inc., 2.20%, 11/1/2024 | 1,027,010 | |||||||
250,000 | SCE Federal Credit Union, 2.75%, 7/24/2023, FCPR DLY -2.5000% 2,3 | 250,464 | |||||||
175,000 | Synovus Financial Corp., 3.13%, 11/1/2022 | 176,354 | |||||||
325,000 | Toronto-Dominion Bank, 1.85%, 9/11/2020 | 324,608 | |||||||
2,926,152 | |||||||||
BIOTECHNOLOGY - 0.6 % | |||||||||
630,000 | Exact Sciences Corp., 1.00%, 1/15/2025 | 686,250 | |||||||
BUILDING MATERIALS - 1.5 % | |||||||||
400,000 | BMC East LLC, 5.50%, 10/1/2024 4 | 389,498 | |||||||
425,000 | Louisiana-Pacific Corp., 4.88%, 9/15/2024 | 370,279 | |||||||
375,000 | Masco Corp., 4.45%, 4/1/2025 | 373,834 | |||||||
425,000 | Masonite International Corp., 5.75%, 9/15/2026 4 | 420,130 | |||||||
265,000 | Vulcan Materials Co., 2.23%, 3/1/2021, Quarterly US LIBOR +0.6500% 5 | 254,930 | |||||||
1,808,671 | |||||||||
COMMERCIAL SERVICES - 1.8 % | |||||||||
500,000 | Ashtead Capital, Inc., 4.13%, 10/1/2024 4 | 460,000 | |||||||
225,000 | Cimpress PLC, 7.00%, 6/15/2026 4 | 199,922 | |||||||
1,000,000 | Local Initiatives Support Corp., 3.01%, 3/1/2022 | 1,018,756 | |||||||
450,000 | United Rentals North America, Inc., 5.88%, 9/15/2026 | 459,169 | |||||||
2,137,847 | |||||||||
COMPUTERS - 0.6 % | |||||||||
700,000 | Apple, Inc., 2.85%, 2/23/2023 | 731,304 | |||||||
DIVERSIFIED FINANCIAL SERVICES - 0.8 % | |||||||||
700,000 | E*TRADE Financial Corp., 2.95%, 8/24/2022 | 691,967 | |||||||
225,000 | Eaton Vance Corp., 3.63%, 6/15/2023 | 233,158 | |||||||
925,125 | |||||||||
Eventide Multi-Asset Income Fund | |||||||||
PORTFOLIO OF INVESTMENTS (Unaudited)(Continued) | |||||||||
March 31, 2020 | |||||||||
Par Value | Fair Value | ||||||||
CORPORATE BONDS - 23.4 % (Continued) | |||||||||
ELECTRIC - 0.8 % | |||||||||
$ 350,000 | Duke Energy Carolinas LLC, 3.35%, 5/15/2022 | $ 360,804 | |||||||
600,000 | MidAmerican Energy Co., 3.10%, 5/1/2027 | 617,938 | |||||||
978,742 | |||||||||
ELECTRONICS - 0.6 % | |||||||||
725,000 | Roper Technologies, Inc., 3.80%, 12/15/2026 | 748,777 | |||||||
ENERGY-ALTERNATE SOURCES - 0.4 % | |||||||||
400,000 | TerraForm Power Operating LLC, 5.00%, 1/31/2028 4 | 421,340 | |||||||
ENGINEERING & CONSTRUCTION - 0.3 % | |||||||||
420,000 | MasTec, Inc., 4.88%, 3/15/2023 | 386,927 | |||||||
HEALTHCARE-PRODUCTS - 0.4 % | |||||||||
400,000 | Hill-Rom Holdings, Inc., 4.38%, 9/15/2027 4 | 397,417 | |||||||
HOME FURNISHINGS - 0.4 % | |||||||||
500,000 | Tempur Sealy International, Inc., 5.50%, 6/15/2026 | 440,350 | |||||||
INSURANCE - 0.8 % | |||||||||
225,000 | Aflac, Inc., 3.25%, 3/17/2025 | 231,592 | |||||||
625,000 | Brown & Brown, Inc., 4.20%, 9/15/2024 | 660,305 | |||||||
891,897 | |||||||||
INTERNET - 0.5 % | |||||||||
525,000 | VeriSign, Inc., 5.25%, 4/1/2025 | 544,034 | |||||||
INVESTMENT COMPANIES - 1.0 % | |||||||||
1,200,000 | Calvert Impact Capital, Inc., 1.50%, 11/13/2020 3 | 1,200,000 | |||||||
IRON/STEEL - 0.3 % | |||||||||
400,000 | Steel Dynamics, Inc., 5.25%, 4/15/2023 | 392,119 | |||||||
MACHINERY-DIVERSIFIED - 0.3 % | |||||||||
400,000 | Mueller Water Products, Inc., 5.50%, 6/15/2026 4 | 390,417 | |||||||
MULTI-NATIONAL - 0.3 % | |||||||||
325,000 | European Investment Bank, 2.50%, 10/15/2024 | 352,437 | |||||||
PACKAGING & CONTAINERS - 0.3 % | |||||||||
400,000 | TriMas Corp., 4.88%, 10/15/2025 4 | 379,750 | |||||||
PHARMACEUTICALS - 1.3 % | |||||||||
850,000 | Neurocrine Biosciences, Inc., 2.25%, 5/15/2024 | 1,093,543 | |||||||
268,000 | Sarepta Therapeutics, Inc., 1.50%, 11/15/2024 | 407,465 | |||||||
1,501,008 | |||||||||
PRIVATE EQUITY - 0.8 % | |||||||||
1,000,000 | Hercules Capital, Inc., 4.63%, 10/23/2022 | 953,813 | |||||||
REAL ESTATE INVESTMENT TRUSTS (REITs) - 4.4 % | |||||||||
675,000 | Alexandria Real Estate Equities, Inc., 3.80%, 4/15/2026 | 675,807 | |||||||
425,000 | AvalonBay Communities, Inc., 2.95%, 5/11/2026 | 425,502 | |||||||
750,000 | Crown Castle International Corp., 3.65%, 9/1/2027 | 761,241 | |||||||
500,000 | Digital Realty Trust LP, 3.95%, 7/1/2022 | 512,369 | |||||||
500,000 | Hat Holdings I LLC, 5.25%, 7/15/2024 4 | 483,127 | |||||||
440,000 | Highwoods Realty LP, 3.20%, 6/15/2021 | 445,190 | |||||||
650,000 | Kilroy Realty LP, 4.75%, 12/15/2028 | 678,539 | |||||||
375,000 | Mid-America Apartments LP, 3.60%, 6/1/2027 | 377,878 | |||||||
850,000 | Welltower, Inc., 2.70%, 2/15/2027 | 809,582 | |||||||
5,169,235 | |||||||||
Eventide Multi-Asset Income Fund | |||||||||
PORTFOLIO OF INVESTMENTS (Unaudited)(Continued) | |||||||||
March 31, 2020 | |||||||||
Par Value | Fair Value | ||||||||
CORPORATE BONDS - 23.4 % (Continued) | |||||||||
RETAIL - 0.8 % | |||||||||
$ 500,000 | Lowe's Cos., Inc., 4.00%, 4/15/2025 | $ 534,826 | |||||||
425,000 | Penske Auto Group, Inc., 5.75%, 10/1/2022 | 396,304 | |||||||
931,130 | |||||||||
SOFTWARE - 0.4 % | |||||||||
400,000 | Open Text Corp., 5.88%, 6/1/2026 4 | 421,780 | |||||||
TELECOMMUNICATIONS - 0.9 % | |||||||||
1,000,000 | Verizon Communications, Inc., 3.88%, 2/8/2029 | 1,108,368 | |||||||
TRANSPORTATION - 0.6 % | |||||||||
715,000 | Kansas City Southern, 2.88%, 11/15/2029 | 690,183 | |||||||
TOTAL CORPORATE BONDS (Cost $28,025,507) | 27,515,073 | ||||||||
MUNICIPAL BONDS - 1.7 % | |||||||||
CALIFORNIA - 1.1 % | |||||||||
1,000,000 | California Health Facilities Financing Authority, 1.90%, 6/1/2021 | 999,750 | |||||||
200,000 | City of Los Angeles CA Wastewater System Revenue, 3.69%, 6/1/2032 | 215,610 | |||||||
100,000 | City of Napa CA Solid Waste Revenue, 2.33%, 8/1/2025 | 102,742 | |||||||
1,318,102 | |||||||||
HAWAII - 0.2 % | |||||||||
150,000 | City & County of Honolulu, HI, 2.52%, 10/1/2026 | 155,969 | |||||||
NEW YORK - 0.4 % | |||||||||
500,000 | New York City Housing Development Corp., 1.35%, 11/1/2026 | 492,987 | |||||||
TOTAL MUNICIPAL BONDS (Cost $1,951,245) | 1,967,058 | ||||||||
ASSET BACKED SECURITIES - 14.2 % | |||||||||
775,343 | FGLMC Collateral, 3.00%, 12/1/2032 | 816,056 | |||||||
458,329 | FGLMC Collateral, 3.00%, 3/1/2034 | 480,588 | |||||||
672,117 | FGLMC Collateral, 3.50%, 11/1/2044 | 719,103 | |||||||
746,852 | FGLMC Collateral, 3.50%, 2/1/2048 | 792,930 | |||||||
255,015 | FGLMC Collateral, 4.00%, 5/1/2032 | 269,163 | |||||||
318,189 | FGLMC Collateral, 4.00%, 11/1/2045 | 344,508 | |||||||
662,071 | FGLMC Collateral, 4.00%, 8/1/2049 | 706,119 | |||||||
1,162,772 | FNMA Collateral, 2.50%, 10/1/2043 | 1,212,590 | |||||||
904,148 | FNMA Collateral, 3.00%, 12/1/2045 | 957,285 | |||||||
1,130,643 | FNMA Collateral, 3.00%, 11/1/2046 | 1,194,634 | |||||||
893,182 | FNMA Collateral, 3.00%, 2/1/2047 | 945,670 | |||||||
983,127 | FNMA Collateral, 3.50%, 2/1/2048 | 1,039,674 | |||||||
591,006 | FNMA Collateral, 3.50%, 3/1/2048 | 629,795 | |||||||
1,625,629 | FNMA Collateral, 3.50%, 6/1/2049 | 1,719,004 | |||||||
301,925 | FNMA Collateral, 4.00%, 7/1/2033 | 318,352 | |||||||
318,424 | FNMA Collateral, 4.00%, 11/1/2047 | 341,117 | |||||||
697,482 | FNMA Collateral, 4.00%, 11/1/2048 | 744,282 | |||||||
862,963 | FNMA Collateral, 4.00%, 2/1/2049 | 920,546 | |||||||
959,837 | FNMA Collateral, 4.00%, 6/1/2049 | 1,023,529 | |||||||
181,650 | FNMA Collateral, 4.50%, 6/1/2044 | 199,278 | |||||||
1,165,182 | GNMA2 Collateral, 3.00%, 1/20/2046 | 1,252,855 | |||||||
TOTAL ASSET BACKED SECURITIES (Cost $16,020,876) | 16,627,078 | ||||||||
COMMERCIAL MORTGAGE BACKED SECURITIES - 1.9 % | |||||||||
1,000,000 | FHLMC Multifamily Structured Pass Through Certs, 2.41%, 8/25/2029 | 1,127,887 | |||||||
1,000,000 | FHLMC Multifamily Structured Pass Through Certs, 2.94%, 4/25/2029 | 1,140,258 | |||||||
TOTAL COMMERCIAL MORTGAGE BACKED SECURITIES (Cost $2,056,606) | 2,268,145 | ||||||||
Eventide Multi-Asset Income Fund | |||||||||
PORTFOLIO OF INVESTMENTS (Unaudited)(Continued) | |||||||||
March 31, 2020 | |||||||||
Par Value | Fair Value | ||||||||
U.S. GOVERNMENT AGENCIES AND OBLIGATIONS - 4.7 % | |||||||||
$ 1,000,000 | Federal Farm Credit Banks Funding Corp., 2.05%, 1/23/2029 | $ 1,089,538 | |||||||
1,000,000 | Federal Farm Credit Banks Funding Corp., 2.58%, 6/15/2027 | 1,116,682 | |||||||
1,400,000 | Federal Home Loan Mortgage Corp., 1.50%, 2/12/2025 | 1,461,567 | |||||||
1,400,000 | Federal National Mortgage Association, 1.88%, 9/24/2026 | 1,490,280 | |||||||
250,000 | Federal National Mortgage Association, 6.25%, 5/15/2029 | 358,196 | |||||||
TOTAL U.S. GOVERNMENT AGENCIES AND OBLIGATIONS (Cost $5,292,205) | 5,516,263 | ||||||||
Shares | |||||||||
SHORT-TERM INVESTMENTS - 0.1 % | |||||||||
101,966 | Fidelity Investments Money Market Fund - Institutional Class, 0.30% 6 | 101,966 | |||||||
TOTAL SHORT-TERM INVESTMENTS (Cost $101,966) | 101,966 | ||||||||
TOTAL INVESTMENTS - 94.7 % (Cost $113,939,008) | $ 111,359,306 | ||||||||
OTHER ASSETS IN EXCESS OF LIABILITIES - 5.3 % | 6,173,701 | ||||||||
TOTAL NET ASSETS - 100.0 % | $ 117,533,007 | ||||||||
FCPR - Federal Reserve Bank Prime Loan Rate US | |||||||||
LLC - Limited Liability Company | |||||||||
LP - Limited Partnership | |||||||||
PLC - Public Limited Company | |||||||||
1. Non-Income producing security. | |||||||||
2. Variable rate, rate shown represents the rate at March 31, 2020. | |||||||||
3. Illiquid security. Total value of all such securities as of March 31, 2020 amounted to $1,450,464 and represented 1.23% of Total Net Assets. | |||||||||
4. 144A Security - Security exempt from registration under Rule 144A of the Securities Act of 1933. The 144A securities represent 3.37% of total net assets. The securities may be resold in transactions exempt from registration typically only to a qualified institutional buyers. Unless otherwise indicated, these securities are not considered to be illiquid. | |||||||||
5. Floating rate, rate shown represents the rate at March 31, 2020. | |||||||||
6. Interest rate reflects seven-day effective yield on March 31, 2020. |
Eventide Funds | |||||||||
SCHEDULE OF INVESTMENTS (Unaudited) | |||||||||
March 31, 2020 | |||||||||
The following is a summary of significant accounting policies followed by the Fund in preparation of the financial statements. These policies are in conformity with accounting principles generally accepted in the United States of America ("GAAP"). The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses for the period. Actual results could differ from those estimates. The Fund is an investment company and accordingly follows the investment company accounting and reporting guidance of the Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic 946 "Financial Services – Investment Companies" including FASB Accounting Standards Update ASU 2013-08. | |||||||||
Security Valuation — Securities listed on an exchange are valued at the last reported sale price at the close of the regular trading session of the exchange on the business day the value is being determined, or in the case of securities listed on NASDAQ, at the NASDAQ Official Closing Price (“NOCP”). In the absence of a sale, such securities shall be valued at the last bid price on the day of valuation. Debt securities (other than short-term obligations) are valued each day by an independent pricing service approved by the Board of Trustees (the “Board”) using methods which include current market quotations from a major market maker in the securities and based on methods which include the consideration of yields or prices of securities of comparable quality, coupon, maturity and type. The Funds may invest in portfolios of open-end or closed-end investment companies (the “underlying funds”). Open-end funds are valued at their respective net asset values as reported by such investment companies. The underlying funds value securities in their portfolios for which market quotations are readily available at their market values (generally the last reported sale price) and all other securities and assets at their fair value by the methods established by the Boards of the underlying funds. The shares of many closed- end investment companies, after their initial public offering, frequently trade at a price per share, which is different than the net asset value per share. The difference represents a market premium or market discount of such shares. There can be no assurances that the market discount or market premium on shares of any closed-end investment company purchased by the Funds will not change. Short- term debt obligations having 60 days or less remaining until maturity, at time of purchase, may be valued at amortized cost, provided each such valuations represent fair value. Options are valued at their closing price on the exchange they are traded on. When no closing price is available, options are valued at their mean price. | |||||||||
In unusual circumstances, instead of valuing securities in the usual manner, the Funds may value securities at “fair value” as determined in good faith by the Funds’ Board, pursuant to the procedures (the “Procedures”) approved by the Board. The Procedures consider, among others, the following factors to determine a security’s fair value: the nature and pricing history (if any) of the security; whether any dealer quotations for the security are available; and possible valuation methodologies that could be used to determine the fair value of the security. Fair value may also be used by the Board if extraordinary events occur after the close of the relevant world market but prior to the New York Stock Exchange close. | |||||||||
The Fund utilizes various methods to measure the fair value of most of its investments on a recurring basis. GAAP establishes a hierarchy that prioritizes inputs to valuation methods. The three levels of input are: Level 1 - Unadjusted quoted prices in active markets for identical assets and liabilities that the Fund has the ability to access. Level 2 - Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument in an inactive market, price for similar instruments, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data. Level 3 - Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available, representing the Fund's own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based on the best information available. | |||||||||
The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. | |||||||||
The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement falls in its entirety, is determined based on the lowest level input that is significant to the fair value measurement in its entirety. | |||||||||
The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The following tables summarize the inputs used as of March 31, 2020 for the Fund's assets and liabilities measured at fair value: | |||||||||
Eventide Dividend Opportunities Fund | |||||||||
Assets | Level 1 | Level 2 | Level 3 | Total | |||||
Common Stocks * | $ 21,859,727 | $ - | $ - | $ 21,859,727 | |||||
Corporate Bonds | - | 800,200 | - | 800,200 | |||||
Limited Partnerships | 2,763,061 | - | - | 2,763,061 | |||||
Preferred Stock | 400,000 | - | - | 400,000 | |||||
Real Estate Investment Trust (REITs) | 7,481,677 | - | - | 7,481,677 | |||||
Short-Term Investments | 3,103,601 | - | - | 3,103,601 | |||||
Total | $ 35,608,066 | $ 800,200 | $ - | $ 36,408,266 | |||||
Eventide Funds | |||||||||
SCHEDULE OF INVESTMENTS (Unaudited) (Continued) | |||||||||
March 31, 2020 | |||||||||
Eventide Gilead Fund | |||||||||
Assets | Level 1 | Level 2 | Level 3 | Total | |||||
Call Options Purchased | $ - | $ 906,250 | $ - | $ 906,250 | |||||
Common Stocks * | 1,832,938,933 | 3,781,589 | - | 1,836,720,522 | |||||
Corporate Bonds | - | 30,000,000 | - | 30,000,000 | |||||
Limited Partnerships | 83,816,760 | - | - | 83,816,760 | |||||
Preferred Stock | - | - | 49,972,265 | 49,972,265 | |||||
Put Options Purchased | 4,444,160 | 1,640,500 | - | 4,444,160 | |||||
Real Estate Investment Trust (REITs) | 46,894,350 | - | - | 46,894,350 | |||||
Short-Term Investments | 10,786,724 | - | - | 10,786,724 | |||||
Total | $ 1,977,240,427 | $ 36,328,339 | $ 49,972,265 | $ 2,063,541,031 | |||||
Eventide Healthcare & Life Sciences Fund | |||||||||
Assets | Level 1 | Level 2 | Level 3 | Total | |||||
Common Stocks * | $ 918,324,507 | $ 5,987,740 | $ - | $ 924,312,247 | |||||
Preferred Stock | - | 11,415,562 | 50,523,401 | 61,938,963 | |||||
Warrants | - | 1,564,560 | - | 1,564,560 | |||||
Short-Term Investments | 49,174,394 | - | - | 49,174,394 | |||||
Total | $ 967,498,901 | $ 18,967,862 | $ 50,523,401 | $ 1,036,990,164 | |||||
Eventide Limited-Term Bond Fund | |||||||||
Assets | Level 1 | Level 2 | Level 3 | Total | |||||
Agency Collateral CMO | $ - | $ 1,858,521 | $ - | $ 1,858,521 | |||||
Asset Backed Securities | - | 9,020,179 | - | 9,020,179 | |||||
Corporate Bonds | - | 24,171,469 | - | 24,171,469 | |||||
Commercial Mortgage Backed Securities | - | 131,819 | - | 131,819 | |||||
Municipal Bonds | - | 1,104,395 | - | 1,104,395 | |||||
Preferred Stock | 712,286 | - | - | 712,286 | |||||
U.S. Government & Agencies Obligations | - | 25,541,613 | - | 25,541,613 | |||||
Total | $ 712,286 | $ 61,827,996 | $ - | $ 62,540,282 | |||||
Eventide Multi-Asset Income Fund | |||||||||
Assets | Level 1 | Level 2 | Level 3 | Total | |||||
Asset Backed Securities | $ - | $ 16,627,078 | $ - | $ 16,627,078 | |||||
Commercial Mortgage Backed Securities | - | 2,268,145 | - | 2,268,145 | |||||
Common Stocks * | 37,309,166 | - | - | 37,309,166 | |||||
Corporate Bonds | - | 27,515,073 | - | 27,515,073 | |||||
Limited Partnerships | 5,789,917 | - | - | 5,789,917 | |||||
Municipal Bonds | - | 1,967,058 | - | 1,967,058 | |||||
Real Estate Investment Trust (REITs) | 14,264,640 | - | - | 14,264,640 | |||||
Short-Term Investments | 101,966 | - | - | 101,966 | |||||
U.S. Government & Agencies Obligations | - | 5,516,263 | - | 5,516,263 | |||||
Total | $ 57,465,689 | $ 53,893,617 | $ - | $ 111,359,306 | |||||
* For a detailed break-out of common stock by industry classification, please refer to the Schedule of Investments | |||||||||
The following is a reconciliation of assets in which level 3 inputs were used in determining value: | |||||||||
Eventide Gilead Fund | |||||||||
Preferred Stock | Total | ||||||||
Beginning Balance 6/30/2019 | $ 68,603,757 | $ 68,603,757 | |||||||
Total realized gain (loss) | (15,175,001) | (15,175,001) | |||||||
Appreciation (Depreciation) | (10,456,490) | (10,456,490) | |||||||
Cost of Purchases | 6,999,999 | 6,999,999 | |||||||
Proceeds from Sales | - | - | |||||||
Net transfers in/out of level 3 | - | - | |||||||
Ending Balance 3/31/2020 | $ 49,972,265 | $ 49,972,265 | |||||||
Eventide Healthcare & Life Sciences Fund | |||||||||
Preferred Stock | Total | ||||||||
Beginning Balance 6/30/2019 | $ 45,139,509 | $ 45,139,509 | |||||||
Total realized gain (loss) | (5,824,998) | (5,824,998) | |||||||
Appreciation (Depreciation) | (4,291,123) | (4,291,123) | |||||||
Cost of Purchases | 20,500,012 | 20,500,012 | |||||||
Proceeds from Sales | - | - | |||||||
Net transfers in/out of level 3 | (4,999,999) | (4,999,999) | |||||||
Ending Balance 3/31/2020 | $ 50,523,401 | $ 50,523,401 | |||||||
Eventide Funds | |||||||||
SCHEDULE OF INVESTMENTS (Unaudited) (Continued) | |||||||||
March 31, 2020 | |||||||||
The significant unobservable inputs used in the fair value measurement of the Funds’ Level 3 private investment in Beta Bionic Series B preferred stock are as follows (1) recent investor transactions in the company (2) updates from the company including new clinical trials data (3) a five-percent discount based on liquidity of the securities held. A significant increase or decrease in the liquidity discount could result in a significantly lower or higher fair value, respectively. | |||||||||
The significant unobservable inputs used in the fair value measurement of the Funds’ Level 3 private investment in Goldfinch Biopharma, Inc. preferred stock are as follows (1) recent investor transactions in the company (2) updates from the company including new clinical trials data (3) a five-percent discount based on liquidity of the securities held. A significant increase or decrease in the liquidity discount could result in a significantly lower or higher fair value, respectively. | |||||||||
The significant unobservable inputs used in the fair value measurement of the Funds’ Level 3 private investment in Pliant Therapeutics Series B, Inc. preferred stock are as follows (1) recent investor transactions in the company (2) updates from the company including new clinical trials data (3) a five-percent discount based on liquidity of the securities held. A significant increase or decrease in the liquidity discount could result in a significantly lower or higher fair value, respectively. | |||||||||
The significant unobservable inputs used in the fair value measurement of the Funds’ Level 3 private investment in Peloton Therapeutics, Inc. preferred stock are as follows (1) recent investor transactions in the company (2) updates from the company including new clinical trials data (3) a five-percent discount based on liquidity of the securities held. A significant increase or decrease in the liquidity discount could result in a significantly lower or higher fair value, respectively. | |||||||||
Fair Value at March 31, 2020 | Valuation Techniques | Unobservable Input | Impact to Valuation | ||||||
$0.86 | Anticipated sale price less discounts plus discounted cash flow of contingent future payments. | 2.5 - 75% range for probability of success of milestones, with a per share discounted weighted average of $0.8168. | Increase (Decrease) in Rate of Success Ratio equals increases (decreases) value | ||||||
The significant unobservable inputs used in the fair value measurement of the Funds’ Level 3 private investment in Praxis Precision Medicines, Inc. preferred stock are as follows (1) recent investor transactions in the company (2) updates from the company including new clinical trials data (3) a five-percent discount based on liquidity of the securities held. A significant increase or decrease in the liquidity discount could result in a significantly lower or higher fair value, respectively. | |||||||||
The significant unobservable inputs used in the fair value measurement of the Funds’ Level 3 private investment in Zeno Pharma LLC Series C preferred stock are as follows (1) recent investor transactions in the company (2) updates from the company including new clinical trials data (3) a five-percent discount based on liquidity of the securities held. A significant increase or decrease in the liquidity discount could result in a significantly lower or higher fair value, respectively. | |||||||||
There was a change in fair valuation measurement inputs from Level 3 to Level 2 for two preferred stocks. Level 2 valuations became available based on the Fund receiving daily valuations via the underlying common stock. | |||||||||
Portfolio Concentration Risk - The Eventide Healthcare & Life Sciences Fund invests primarily in equity and equity-related securities of companies in the healthcare and life sciences sectors that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services including, but not limited to, biotechnology, pharmaceuticals, diagnostics, life science tools, medical devices, healthcare information technology, healthcare services, synthetic biology, agricultural and environmental management, and pharmaceutical manufacturing products and services. Because of its focus on healthcare and life science companies, the Eventide Healthcare & Life Sciences Fund’s investment performance will be closely tied to many factors which affect those companies. As a result, the Eventide Healthcare & Life Sciences Fund’s net asset value is more likely to have greater fluctuations than that of a fund which invests in other industries. | |||||||||
Option Risk - The Funds are subject to equity price risk in the normal course of pursuing their investment objectives and may purchase or sell options to help hedge against risk. When the Funds write a call option, an amount equal to the premium received is included in the statement of assets and liabilities as a liability. The amount of the liability is subsequently marked-to-market to reflect the current market value of the option. If an option expires on its stipulated expiration date or if the Funds enter into a closing purchase transaction, a gain or loss is realized. If a written call option is exercised, a gain or loss is realized for the sale of the underlying security and the proceeds from the sale are increased by the premium originally received. As writer of an option, the Funds have no control over whether the option will be exercised and, as a result, retains the market risk of an unfavorable change in the price of the security underlying the written option. | |||||||||
Each Fund may purchase put and call options. Put options are purchased to hedge against a decline in the value of securities held in the Fund’s portfolio. If such a decline occurs, the put options will permit the Fund to sell the securities underlying such options at the exercise price, or to close out the options at a profit. The premium paid for a put or call option plus any transaction costs will reduce the benefit, if any, realized by the Fund upon exercise of the option, and, unless the price of the underlying security rises or declines sufficiently, the option may expire worthless to the Fund. In addition, in the event that the price of the security in connection with which an option was purchased moves in a direction favorable to the Fund, the benefits realized by the Fund as a result of such favorable movement will be reduced by the amount of the premium paid for the option and related transaction costs. Written and purchased options are non-income producing securities. With purchased options, there is minimal counterparty risk to the Fund since these options are exchange traded and the exchange’s clearinghouse, as counterparty to all exchange traded options, guarantees against a possible default. During the period ended March 31, 2020, the Gilead Fund had realized gain of $10,969,857 and the Healthcare & Life Sciences Fund had realized loss of $682,154 from options contracts. | |||||||||
Eventide Funds | |||||||||
SCHEDULE OF INVESTMENTS (Unaudited) (Continued) | |||||||||
March 31, 2020 | |||||||||
Restricted securities include securities that have not been registered under the Securities Act of 1933, as amended, and securities that are subject to restrictions on resale. Each Fund may invest in restricted securities that are consistent with the Fund’s investment objectives and investment strategies. The Funds will not invest in a restricted security if, immediately after and as a result of the investment in such security, more than 15% of a Fund’s net assets would be invested in illiquid securities. In some cases, the issuer of restricted securities has agreed to register such securities for resale, at the issuer’s expense either upon demand by the Funds or in connection with another registered offering of the securities. Investments in restricted securities are valued at fair value as determined in good faith in accordance with procedures adopted by the Board. It is possible that the estimated value may differ significantly from the amount that might ultimately be realized in the near term, and the difference could be material. | |||||||||
The identified cost of investments in securities owned by the Fund for federal income for federal income tax purposes and its respective gross unrealized appreciation and depreciation at March 31, 2020, were as follows: | |||||||||
Tax Cost | Gross Unrealized Appreciation | Gross Unrealized Depreciation | Net Unrealized Appreciation / (Depreciation) | ||||||
Eventide Dividend Opportunities Fund | $ 39,202,968 | $ 845,185 | $ (3,639,887) | $ (2,794,702) | |||||
Eventide Gilead Fund | 1,810,029,049 | 467,239,069 | (213,727,087) | 253,511,982 | |||||
Eventide Healthcare & Life Sciences Fund | 964,792,749 | 214,558,998 | (142,361,583) | 72,197,415 | |||||
Eventide Limited-Term Bond Fund | 62,536,567 | 744,158 | (740,443) | 3,715 | |||||
Eventide Multi-Asset Fund | 113,348,802 | 4,205,859 | (6,195,355) | (1,989,496) |